Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure disorder in which the body fails to produce enough red blood cells. It affects roughly 7 out of every million babies born and is typically diagnosed in the first year of life. Unlike other forms of anemia, the problem in DBA isn’t a lack of iron or nutrients. Instead, the bone marrow’s red blood cell factory is fundamentally broken at the genetic level, leaving infants pale, fatigued, and dependent on medical intervention to survive.
Why the Bone Marrow Can’t Make Red Blood Cells
Every cell in your body relies on tiny molecular machines called ribosomes to build proteins. In DBA, a genetic mutation disrupts how ribosomes are assembled. When ribosome production goes wrong, the early-stage cells destined to become red blood cells (called erythroid progenitors) essentially self-destruct before they mature. A bone marrow sample from someone with DBA typically shows fewer than 5% of the red blood cell precursors you’d expect to find.
The self-destruction happens through a specific chain of events. When ribosome assembly is incomplete, leftover ribosomal protein pieces accumulate inside the cell. These stray pieces interfere with a key safety mechanism, ultimately activating a protein called p53, which acts as a cellular emergency brake. Once p53 is switched on, it forces the cell to stop dividing or triggers programmed cell death. Red blood cell precursors seem particularly vulnerable to this process, possibly because they need to produce enormous quantities of protein (especially hemoglobin) during a very short window of rapid growth. When ribosome production can’t keep up with that demand, the emergency brake gets pulled.
The Genetic Mutations Behind DBA
DBA is caused by mutations in genes that encode ribosomal proteins. So far, researchers have identified about 20 different genes that can cause the condition when one copy is defective. You only need a mutation in one of your two copies of the gene (a heterozygous mutation) for the disease to develop.
The most commonly affected gene is RPS19, which accounts for roughly 25% of all DBA cases. The next most frequent are RPL5 and RPS26, each responsible for about 7% of cases, followed by RPL11 at around 5%. In a significant portion of patients, no known gene mutation can be identified at all, suggesting there are additional genetic causes still undiscovered. DBA can be inherited from a parent who carries the mutation, but many cases arise as new (spontaneous) mutations with no family history.
How DBA Presents in Infants
More than 90% of DBA cases become apparent before a child’s first birthday. The median age when symptoms first show up is around 8 weeks, with a formal diagnosis typically made by about 12 weeks. Parents usually notice that their baby looks unusually pale and seems listless or excessively sleepy, signs of the severe anemia that defines the condition. Boys and girls are affected equally.
About half of children with DBA also have physical abnormalities present at birth. The most recognizable are malformations of the thumbs and hands, including a distinctive three-boned (triphalangeal) thumb that looks more like a finger. Craniofacial differences are also common, such as unusually small ears. Some children are born with heart defects like holes between the heart’s chambers, kidney abnormalities such as a horseshoe-shaped kidney, or short stature that persists into adulthood. In rare cases, the anemia is severe enough to cause dangerous fluid buildup in the fetus before birth.
How DBA Is Diagnosed
Doctors suspect DBA when a young infant has severe anemia with very low red blood cell production but normal levels of white blood cells and platelets. A bone marrow sample confirms the picture: the marrow looks healthy overall but is nearly devoid of the early red blood cell precursors that should be abundant.
A helpful supporting test measures the level of an enzyme called adenosine deaminase inside red blood cells (eADA). In DBA, this enzyme is elevated. A level at or above 1 international unit per gram of hemoglobin is 95% specific for DBA when compared to other bone marrow failure syndromes, making it a useful way to distinguish DBA from conditions that can look similar. Genetic testing can then confirm the diagnosis by identifying a mutation in one of the known ribosomal protein genes, though not all patients will have a detectable mutation.
Treatment: Steroids, Transfusions, or Transplant
The first-line treatment is corticosteroid medication, typically started at a dose based on the child’s weight and given for up to four weeks. An adequate response means the child’s hemoglobin rises above 9 g/dL without needing a blood transfusion. If hemoglobin keeps dropping or the child needs another transfusion despite the medication, the steroid trial is considered a failure and stopped. Some children fall into a gray zone with hemoglobin between 8 and 9 g/dL, and doctors may attempt a gradual dose reduction to see if the response holds.
Children who don’t respond to steroids, or who can’t tolerate the side effects of long-term steroid use, rely on regular blood transfusions to maintain safe hemoglobin levels. This keeps them alive and functioning but introduces a serious secondary problem: iron overload. Each unit of transfused blood delivers a large dose of iron that the body has no efficient way to eliminate. Once a patient has received roughly 10 to 12 transfusions, or when blood ferritin levels reach about 1,000 micrograms per liter, iron chelation therapy is started. This involves medication that binds excess iron so the body can excrete it, protecting the heart and liver from iron-related damage.
The only cure for DBA is a stem cell transplant. When a matched sibling donor is available, the long-term survival rate is approximately 87%. However, outcomes with unrelated donors have historically been much worse, with survival rates dropping substantially. This makes finding a well-matched donor critically important, and the decision to pursue transplant involves weighing the risks of the procedure against the burden of lifelong transfusions or steroid dependence.
Spontaneous Remission
An unusual feature of DBA is that some patients experience spontaneous remission, meaning their bone marrow begins producing red blood cells on its own without ongoing treatment. This can happen in childhood or later in life, and the reasons are not well understood. Remission may be temporary or lasting, and patients in remission still carry the underlying genetic mutation, which means they require continued monitoring.
Long-Term Cancer Risk
People with DBA face an elevated lifetime risk of developing cancer. Data from the Diamond Blackfan Anemia Registry shows that by age 46, the cumulative incidence of cancer (solid tumors and leukemia combined) is roughly 22%. Solid tumors tend to appear earlier, with about 3% of patients developing one by age 30. Acute myeloid leukemia (AML) emerges later, with cases beginning to accumulate after age 40 and reaching about 5% by age 46.
The median survival for people with DBA is approximately 56 years. By age 30, about 11% of registry patients had died from various causes, and 16% had undergone a bone marrow transplant. These numbers underscore that DBA is a lifelong condition requiring regular follow-up, not just for anemia management but for early detection of secondary cancers and monitoring of organ function in those receiving chronic transfusions.